<DOC>
	<DOCNO>NCT02056730</DOCNO>
	<brief_summary>The dialysis patient chronic kidney disease parathyroid hormone level great equal 800 Pg per ml divide two group randomize 1:1 , one group receive medication control group receive medication . By group receive take 25 mg per day get default dose dose adjust accord level calcium parathyroid hormone . By adjust dose 25 mg every 3 week period 12 week , drug 25-75 mg dose , maximum dose 100 mg per day ( week 3 , 6 , 9 ) . After follow-up treatment week 12 , 24 36 blood , ultrasound test parathyroid gland , abdominal x-ray side . To evaluate change without drug .Unless track treatment patient low blood calcium level 8.4 mg per dL . No dose adjustment . regpara blood calcium level less 7.5 mg per deciliter . Must stop take medication patient control group receive standard treatment . Which consist dose vitamin D sterol parathyroid surgery . Unable control level parathyroid hormone vitamin D sterol . While participate research allow adjust amount vitamin D sterol two group . But amount dialysate calcium phosphate binder adjust appropriate healthcare fine .</brief_summary>
	<brief_title>The Study Efficacy Safety REGPARA Drug Dialysis Patients Have High Blood Levels Parathyroid</brief_title>
	<detailed_description>The renal impairment cause FGF-23 resistance congestion phosphate stimulate secretion parathyroid hormone ( PTH ) parathyroid gland cause secondary hyperparathyroidism . They also find high level FGF-23 also risk factor vascular calcification . The Chronic Kidney Disease-Mineral Bone Disorder ( CKD-MBD ) disorder cause renal impairment cause abnormality occur body . Can summarize three main part follow : 1 ) The disorder mineral hormone ( laboratory abnormality ) hyperphosphatemia , secondary hyperparathyroidism . 2 ) The disorder bone ( bone abnormality ) , formerly know renal osteodystrophy 3 ) The vascular calcification result happen increase risk heart disease stroke ( cardiovascular disease ) , break bone ( fracture ) death rate ( mortality ) . The secondary hyperparathyroidism . PTH secretion parathyroid glands normal major cause congestion phosphate , reduce level 1,25-dihydroxyvitamin D [ 1,25 ( OH ) 2D ] blood decrease blood calcium level decrease calcium level blood low . result calcium ( calcium sense receptor CaSR ) parathyroid gland make parathyroid cell signal increase PTH secretion . That PTH increase continuously long run cause destruction bone call bone decay know `` osteitis fibrosa '' . Some patient bone fracture . Important characteristic osteitis fibrosa increase bone destruction ( osteoclastic bone resorption ) . In addition , bone marrow may also find associate bone marrow fibrosis cause anemia respond erythropoietin .</detailed_description>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<criteria>1 . The patient age equal 18 year enrollment date . 2 . The patient get dialysis 3 time per week 3 . The parathyroid hormone level great equal 800 pg per mL screen 4.The calcium level blood great equal 9 mg per dL . 1 . The patient parathyroid gland surgery . 2 . The patient history seizure within 12 week randomize . 3 . The patient schedule surgery kidney 4 . The patient expect parathyroid gland surgery within 6 month 5 . The liver function abnormality , include SGOT , SGPT , two fold 6 . The patient history receive drug bisphosphonates group expect receive study . 7 . The patient history cancer . Pregnant woman . Lactating woman . And sepsis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>chronic hemodialysis patient</keyword>
	<keyword>Hyperparathyroidism</keyword>
	<keyword>Regpara</keyword>
	<keyword>FGF 23</keyword>
</DOC>